rEVO Biologics Overview
- Year Founded
-
1993
- Status
-
Acquired/Merged
- Employees
-
17
- Latest Deal Type
-
M&A
- Financing Rounds
-
4
rEVO Biologics General Information
Description
Manufacturer of therapeutic protein products based in Framingham, Massachusetts. The Company is engaged in the development and production of human therapeutic proteins through transgenic technology. It has produced ATryn, Antithrombin (Recombinant) a plasma-free antithrombin concentrate.
Contact Information
Corporate Office
- 175 Crossing BLVD
- Framingham, MA 01701
- United States
Corporate Office
- 175 Crossing BLVD
- Framingham, MA 01701
- United States
rEVO Biologics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
rEVO Biologics Comparisons
Industry
Financing
Details
rEVO Biologics Competitors (40)
One of rEVO Biologics’s 40 competitors is Novavax, a Corporation company based in Gaithersburg, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Novavax | Corporation | Gaithersburg, MD | ||||
| Takeda Pharmaceutical | Corporation | Tokyo, Japan | ||||
| Protagonist Therapeutics | Formerly VC-backed | Newark, CA | ||||
| CSL Behring (Biotechnology) | Corporation | Vienna, Austria | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom |
rEVO Biologics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
rEVO Biologics Patents
rEVO Biologics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2014040024-A1 | The use of antibodies in treating hiv infection and suppressing hiv transmission | Inactive | 10-Sep-2012 | ||
| WO-2014022748-A1 | The use of antithrombin in extracorporeal membrane oxygenation | Inactive | 03-Aug-2012 | ||
| US-20140194360-A1 | Use of antithrombin in extracorporeal membrane oxygenation | Active | 03-Aug-2012 | ||
| US-9511087-B2 | Use of antithrombin in extracorporeal membrane oxygenation | Inactive | 03-Aug-2012 | ||
| WO-2013138271-A1 | The use of antithrombin in the treatment of pre-eclampsia | Inactive | 12-Mar-2012 | A61K38/57 |
rEVO Biologics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
rEVO Biologics FAQs
-
When was rEVO Biologics founded?
rEVO Biologics was founded in 1993.
-
Where is rEVO Biologics headquartered?
rEVO Biologics is headquartered in Framingham, MA.
-
What is the size of rEVO Biologics?
rEVO Biologics has 17 total employees.
-
What industry is rEVO Biologics in?
rEVO Biologics’s primary industry is Pharmaceuticals.
-
Is rEVO Biologics a private or public company?
rEVO Biologics is a Private company.
-
What is the current valuation of rEVO Biologics?
The current valuation of rEVO Biologics is .
-
What is rEVO Biologics’s current revenue?
The current revenue for rEVO Biologics is .
-
How much funding has rEVO Biologics raised over time?
rEVO Biologics has raised $44.2M.
-
Who are rEVO Biologics’s competitors?
Novavax, Takeda Pharmaceutical, Protagonist Therapeutics, CSL Behring (Biotechnology), and Adaptimmune Therapeutics are some of the 40 competitors of rEVO Biologics.
-
When was rEVO Biologics acquired?
rEVO Biologics was acquired on 02-Dec-2010.
-
Who acquired rEVO Biologics?
rEVO Biologics was acquired by LFB Group.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
